X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ACTAVIS (US) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   ACTAVIS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
ACTAVIS
Dec-14
TORRENT PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,76818,769-   
Low Rs1,18611,448-   
Sales per share (Unadj.) Rs346.13,379.7-  
Earnings per share (Unadj.) Rs55.2-421.8-  
Cash flow per share (Unadj.) Rs73.3310.1-  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.17,330.5-  
Shares outstanding (eoy) m169.22265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.34.5 95.4%   
Avg P/E ratio x26.8-35.8 -74.7%  
P/CF ratio (eoy) x20.148.7 41.3%  
Price / Book Value ratio x5.72.1 278.7%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,8874,017,345 6.2%   
No. of employees `00011.821.6 54.5%   
Total wages/salary Rs m9,9340-   
Avg. sales/employee Rs Th4,971.541,604.9 11.9%   
Avg. wages/employee Rs Th843.20-   
Avg. net profit/employee Rs Th792.4-5,191.9 -15.3%   
INCOME DATA
Net Sales Rs m58,569898,666 6.5%  
Other income Rs m2,233-2,243 -99.6%   
Total revenues Rs m60,802896,423 6.8%   
Gross profit Rs m13,773115,446 11.9%  
Depreciation Rs m3,069194,594 1.6%   
Interest Rs m2,05628,346 7.3%   
Profit before tax Rs m10,881-109,736 -9.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,050 0.0%   
Tax Rs m1,545-5,642 -27.4%   
Profit after tax Rs m9,336-112,144 -8.3%  
Gross profit margin %23.512.8 183.0%  
Effective tax rate %14.25.1 276.2%   
Net profit margin %15.9-12.5 -127.7%  
BALANCE SHEET DATA
Current assets Rs m53,841473,482 11.4%   
Current liabilities Rs m31,612345,307 9.2%   
Net working cap to sales %38.014.3 266.1%  
Current ratio x1.71.4 124.2%  
Inventory Days Days9758 167.5%  
Debtors Days Days8466 126.4%  
Net fixed assets Rs m42,079109,736 38.3%   
Share capital Rs m8460-   
"Free" reserves Rs m42,6550-   
Net worth Rs m43,5011,949,173 2.2%   
Long term debt Rs m22,4081,021,405 2.2%   
Total assets Rs m101,2503,572,192 2.8%  
Interest coverage x6.3-2.9 -219.2%   
Debt to equity ratio x0.50.5 98.3%  
Sales to assets ratio x0.60.3 229.9%   
Return on assets %11.3-2.3 -479.6%  
Return on equity %21.5-5.8 -373.0%  
Return on capital %19.6-3.0 -651.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,7620-   
CASH FLOW
From Operations Rs m10,127154,318 6.6%  
From Investments Rs m-7,869-369,497 2.1%  
From Financial Activity Rs m-1,918207,604 -0.9%  
Net Cashflow Rs m212-7,575 -2.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.8 Rs / USD

Compare TORRENT PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare TORRENT PHARMA With: WOCKHARDT LTD.  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  ALKEM LABORATORIES  



Today's Market

Sensex Ends Volatile Day Flat; Pharma Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day flat.

Related Views On News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jul 19, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - BIOCON LTD COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS